Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2026
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability targeting medicine for secondary progressive multiple sclerosis without relapses
23 June 2026 - The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis without relapses ...
Posted by Michael Wonder on 23 Jun 2026
Laboratoires Pierre Fabre receives European Commission approval for Braftovi (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer
22 June 2026 - Laboratoires Pierre Fabre announced today that the European Commission has approved Braftovi (encorafenib) in combination with cetuximab ...
Posted by Michael Wonder on 23 Jun 2026
AbbVie announces European Commission approval of Skyrizi (risankizumab) for the treatment of paediatric patients with moderate to severe plaque psoriasis
23 June 2026 - AbbVie today announced that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and ...
Posted by Michael Wonder on 23 Jun 2026
Arrowhead Pharmaceuticals receives marketing authorisation in the European Union for Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome
22 June 2026 - Arrowhead Pharmaceuticals today announced that the European Commission has formally granted marketing authorization for Redemplo (plozasiran), ...
Posted by Michael Wonder on 23 Jun 2026
AbbVie announces European Commission approval of Maviret (glecaprevir/pibrentasvir) for people with acute hepatitis C virus infection
23 June 2026 - AbbVie today announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral therapy for ...
Posted by Michael Wonder on 23 Jun 2026
European Commission approves Trodelvy as a first-line treatment for metastatic triple negative breast cancer patients not candidates for PD-(L)1 inhibitors
23 June 2026 - Gilead Sciences today announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) ...
Posted by Michael Wonder on 09 Jun 2026
Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
8 June 2026 - The European Commission has approved Sarclisa (isatuximab) subcutaneous in combination with standard of care regimens for the ...
Posted by Michael Wonder on 06 Jun 2026
Chiesi Global Rare Diseases announces European Commission approval of Lojuxta (lomitapide) capsules for paediatric use in homozygous familial hypercholesterolaemia
5 June 2026 - Chiesi Global Rare Diseases today announced that the European Commission has approved lomitapide capsules for use in ...
Posted by Michael Wonder on 04 Jun 2026
European Commission approves Amgen's Imdylltra for the treatment of extensive-stage small cell lung cancer
1 June 2026 - Amgen today announced that the European Commission has granted marketing authorisation for Imdylltra (tarlatamab) as a ...
Posted by Michael Wonder on 04 Jun 2026
AbbVie announces European Commission approval of Aquipta (atogepant) for the acute treatment of migraine in adults
2 June 2026 - AbbVie today announced that the European Commission has approved Aquipta (atogepant) for the acute treatment of migraine ...
Posted by Michael Wonder on 02 Jun 2026
Zepzelca (lurbinectedin) in combination with atezolizumab approved by the European Commission as first-line maintenance therapy for extensive-stage small cell lung cancer
1 June 2026 - Immedica today announces that the European Commission has granted marketing authorisation for Zepzelca (lurbinectedin), in combination with ...
Posted by Michael Wonder on 01 Jun 2026
Bristol Myers Squibb announces Opdivo (nivolumab) in combination with AVD receives expanded EU label with approval in frontline advanced classical Hodgkin lymphoma
1 June 2026 - Bristol Myers Squibb today announced that the European Commission has approved Opdivo (nivolumab) in combination with ...
Posted by Michael Wonder on 01 Jun 2026
AbbVie announces European Commission authorisation of expanded label for Venclyxto (venetoclax) to include additional combinations in previously untreated chronic lymphocytic leukaemia
29 May 2026 - AbbVie today announced that the European Commission (EC) has authorised an expanded label for Vencylxto (venetoclax) to ...
Posted by Michael Wonder on 26 May 2026
Avanzanite Bioscience’s partner Agios announces Pyrukynd (mitapivat) approval in the European Union for adults with thalassaemia
22 May 2026 - Avanzanite Bioscience today reported that its partner, Agios Pharmaceuticals announced that the European Commission has granted marketing ...
Posted by Michael Wonder on 25 May 2026
New medicine for two types of pulmonary fibrosis
22 May 2026 - Jascayd slowed loss of lung function in patients with idiopathic or progressive pulmonary fibrosis. ...